Axa SA decreases the position in Edwards Lifesciences Co. (NYSE:EW)

Axa SA reduced its stake in Edwards Lifesciences Co shares. (NYSE:EW – Free Report) by 27.1% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,002,502 shares of the medical research company’s stock after selling 373,433 shares during the period. Axa SA owned 0.17% of Edwards Lifesciences worth $92,601,000 at the end of the most recent reporting period.

Other large investors have recently bought and sold shares of the company. Crewe Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $28,000. First Community Trust NA purchased a new stake in Edwards Lifesciences in the second quarter valued at about $29,000. Riverview Trust Co acquired a new stake in shares of Edwards Lifesciences in the 1st quarter worth $34,000. Webster Bank NA acquired a new position in shares of Edwards Lifesciences in the second quarter valued at $39,000. Finally, Rise Advisors LLC boosted its holdings in shares of Edwards Lifesciences by 125.0% in the 1st quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s shares.

The Wall Street analyst weighs in

Several analysts recently issued reports on the company. Oppenheimer restated an “outperform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a report on Thursday, September 12th. Royal Bank of Canada decreased their price target on Edwards Lifesciences from $101.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th . UBS Group dropped their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 10th. Finally, Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and decreased their price target for the company from $105.00 to $75.00 in a research note from Thursday, July 25. Sixteen research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $79.82, according to MarketBeat.com.

Get the latest research report on EW

Insiders place their bets

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The sale was disclosed in a filing with the SEC, which is accessible via this hyperlink. In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,378,659.44. The sale was disclosed in a legal filing with the SEC, which is accessible via this link. Also, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock worth $1,218,138 in the last three months. Company insiders own 1.29% of the company’s shares.

Edwards Lifesciences trades down 1.4%

NYSE EW opened at $65.40 on Thursday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87, and a current ratio of 3.71. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a 50-day simple moving average of $69.02 and a 200-day simple moving average of $82.43. The firm has a market cap of $39.40 billion, a PE ratio of 28.19, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW – Get Free Report ) last posted its earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The company had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a return on equity of 22.35% and a net margin of 24.55%. Edwards Lifesciences’s quarterly revenue was up 6.7% compared to the same quarter last year. In the same period last year, the firm posted earnings of $0.66 per share. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan and internationally. Offers transcatheter heart valve replacement products for minimally invasive aortic heart valve replacement within the Edwards SAPIEN family of valve systems; and transcatheter heart valve repair and replacement products for the treatment of mitral and tricuspid valve disease under the names PASCAL PRECISION and Cardioband.

See Also

Want to see what other hedge funds own EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Edwards Lifesciences Co. (NYSE:EW – Free Report).

Get news and reviews for Edwards Lifesciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Edwards Lifesciences and related companies with MarketBeat.com ‘s FREE daily email newsletter.